Skip to main content

Peer Review reports

From: Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results

Original Submission
9 Aug 2017 Submitted Original manuscript
30 Aug 2017 Author responded Author comments - Louise Hiller
Resubmission - Version 2
30 Aug 2017 Submitted Manuscript version 2
24 Sep 2017 Reviewed Reviewer Report - Fabio Puglisi
14 Oct 2017 Reviewed Reviewer Report - Stefania Gori
19 Oct 2017 Reviewed Reviewer Report - saroj Niraula
21 Oct 2017 Reviewed Reviewer Report - Filipa Lynce
14 Dec 2017 Author responded Author comments - Louise Hiller
Resubmission - Version 3
14 Dec 2017 Submitted Manuscript version 3
20 Feb 2018 Reviewed Reviewer Report - saroj Niraula
20 Feb 2018 Reviewed Reviewer Report - Stefania Gori
20 Mar 2018 Author responded Author comments - Louise Hiller
Resubmission - Version 4
20 Mar 2018 Submitted Manuscript version 4
22 Mar 2018 Author responded Author comments - Louise Hiller
Resubmission - Version 5
22 Mar 2018 Submitted Manuscript version 5
Publishing
26 Mar 2018 Editorially accepted
5 Apr 2018 Article published 10.1186/s12885-018-4307-8

You can find further information about peer review here.

Back to article page